Cargando…

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution

BACKGROUND: Previous studies have reported up to 50% of ductal carcinoma in situ (DCIS), is HER2 positive, but the frequency of HER2-positive invasive breast cancer (IBC) is lower. The aim of this study is to characterise HER2 status in DCIS and assess its prognostic value. METHODS: HER2 status was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miligy, Islam M., Toss, Michael S., Gorringe, Kylie L., Lee, Andrew H. S., Ellis, Ian O., Green, Andrew R., Rakha, Emad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738110/ https://www.ncbi.nlm.nih.gov/pubmed/31065110 http://dx.doi.org/10.1038/s41416-019-0436-3

Ejemplares similares

The prognostic significance of immune microenvironment in breast ductal carcinoma in situ
por: Toss, Michael S., et al.
Publicado: (2020)

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS)
por: Toss, Michael S., et al.
Publicado: (2018)

The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS)
por: Al-Kawaz, Abdulbaqi, et al.
Publicado: (2021)

The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
por: Miligy, Islam M., et al.
Publicado: (2020)

Correction: The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
por: Miligy, Islam M., et al.
Publicado: (2020)

A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
por: Klimov, Sergey, et al.
Publicado: (2019)

Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis
por: Gorringe, Kylie L., et al.
Publicado: (2017)

Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape
por: Kader, Tanjina, et al.
Publicado: (2018)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Improving mitotic cell counting accuracy and efficiency using phosphohistone‐H3 (PHH3) antibody counterstained with haematoxylin and eosin as part of breast cancer grading
por: Ibrahim, Asmaa, et al.
Publicado: (2022)

Refining the definition of HER2‐low class in invasive breast cancer
por: Atallah, Nehal M, et al.
Publicado: (2022)

Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis
por: Shiino, Sho, et al.
Publicado: (2022)

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development
por: Aljohani, Abrar I., et al.
Publicado: (2022)

The characteristics and clinical significance of atypical mitosis in breast cancer
por: Lashen, Ayat, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Chemokine (C‐C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma
por: Sonbul, Sultan N, et al.
Publicado: (2017)

Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases
por: Rakha, Emad A., et al.
Publicado: (2021)

Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast
por: Pang, Jia-Min B., et al.
Publicado: (2015)

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
por: Althobiti, Maryam, et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Biological and clinical significance of PARP1 protein expression in breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification
por: Powe, Desmond G, et al.
Publicado: (2009)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
por: Joseph, Chitra, et al.
Publicado: (2020)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2020)

The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ
por: Gilleard, Onur, et al.
Publicado: (2008)

The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma
por: Kader, Tanjina, et al.
Publicado: (2020)

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer
por: Kariri, Yousif A., et al.
Publicado: (2019)

Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers
por: Ogden, Angela, et al.
Publicado: (2020)

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
por: Mesquita, Katia A., et al.
Publicado: (2021)

Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome
por: Syed, Binafsha M., et al.
Publicado: (2021)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Updated UK Recommendations for HER2 assessment in breast cancer
por: Rakha, Emad A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6jdu6gve7131apnkaev86ds30f